NEKs are proteins that are involved in various cell processes and play important roles in the formation and development of cancer. However, few studies have examined the role of NEKs in the development of non-small-cell lung carcinoma (NSCLC). To address this problem, the Oncomine, UALCAN, and the Human Protein Atlas databases were used to analyze differential NEK expression and its clinicopathological parameters, while the Kaplan–Meier, cBioPortal, GEPIA, and DAVID databases were used to analyze survival, gene mutations, similar genes, and biological enrichments. The rate of NEK family gene mutation was high (> 50%) in patients with NSCLC, in which NEK2/4/6/8/ was overexpressed and significantly correlated with tumor stage and nodal metastasis status. In addition, the high expression of NEK2/3mRNA was significantly associated with poor prognosis in patients with NSCLC, while high expression of NEK1/4/6/7/8/9/10/11mRNA was associated with good prognosis. In summary, these results suggest that NEK2/4/6/8 may be a potential prognostic biomarker for the survival of patients with NSCLC.

Objective: To investigate the expression and prognostic significance of protein kinase DNA activated catalytic subunit (PRKDC) in non-small cell lung cancer (NSCLC). Methods: oncomine, ualcan, human protein Altas, Kaplan Meier plot and c-bioportal databases were searched to analyze the mRNA expression, protein expression, clinicopathological parameters, prognosis, survival and gene mutation of PRKDC in NSCLC and normal lung tissues.Results: the overexpression of PRKDC mRNA and protein in pathological tissues was significantly correlated with the stage of lung adenocarcinoma (luad) and lung squamous cell carcinoma (lusc), smoking habits, gender, race and lymph node metastasis, and significantly correlated with the shortening of overall survival rate (OS) of NSCLC patients. At the same time, PRKDC had a high mutation rate in NSCLC（ LUAD:23% ，LUSC:19% ）The patients with luad had shorter OS and disease-free survival Survival rate (DPS) was significantly correlated.Conclusion: PRKDC may be a biomarker for the prognosis of NSCLC patients.